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abstractBACKGROUND: Estimates of children and adolescents with disabilities worldwide are needed to
inform global intervention under the disability-inclusive provisions of the Sustainable
Development Goals. We sought to update the most widely reported estimate of 93 million
children ,15 years with disabilities from the Global Burden of Disease Study 2004.
METHODS: We analyzed Global Burden of Disease Study 2017 data on the prevalence of
childhood epilepsy, intellectual disability, and vision or hearing loss and on years lived with
disability (YLD) derived from systematic reviews, health surveys, hospital and claims
databases, cohort studies, and disease-specific registries. Point estimates of the prevalence
and YLD and the 95% uncertainty intervals (UIs) around the estimates were assessed.
RESULTS: Globally, 291.2 million (11.2%) of the 2.6 billion children and adolescents (95% UI:
249.9–335.4 million) were estimated to have 1 of the 4 specified disabilities in 2017. The
prevalence of these disabilities increased with age from 6.1% among children aged ,1 year to
13.9% among adolescents aged 15 to 19 years. A total of 275.2 million (94.5%) lived in low-
and middle-income countries, predominantly in South Asia and sub-Saharan Africa. The top 10
countries accounted for 62.3% of all children and adolescents with disabilities. These
disabilities accounted for 28.9 million YLD or 19.9% of the overall 145.3 million (95% UI:
106.9–189.7) YLD from all causes among children and adolescents.
CONCLUSIONS: The number of children and adolescents with these 4 disabilities is far higher than
the 2004 estimate, increases from infancy to adolescence, and accounts for a substantial
proportion of all-cause YLD.
WHAT’S KNOWN ON THIS SUBJECT: The World Disability Report 2011
indicated that at least 93 million (∼5.1%) children ,15 years old had
a moderate-to-severe disability and 13 million (0.7%) had a severe disability
on the basis of the Global Burden of Disease Study 2004.
WHAT THIS STUDY ADDS: More than 291 million children aged ,20 years
had epilepsy and intellectual and sensory disabilities in 2017. The top 10
countries accounted for 62% of the children with these disabilities, and 95%
lived in low and middle income countries.
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The United Nations’ Sustainable
Development Goals (SDGs) mandate
programs that will ensure inclusive
and equitable quality education
and promote lifelong learning
opportunities for all children and
adolescents, including those with
disabilities.1 The majority of children
with disabilities live in low- and
middle-income countries (LMICs)2,3
and are less likely to go to school,
or if they do attend school, they
are more likely to leave school before
completing primary or secondary
education, resulting in considerable
barriers to work and gainful
employment.4–6 They are frequently
marginalized in society and are
disproportionately vulnerable to
neglect, abuse, poverty, and violence.4
Thus, children and adolescents with
disabilities are prone to be left behind
under the SDGs era without timely
and appropriate intervention from
early childhood.4,5
Limited global data exist on children
and adolescents with disabilities
because of insufficient investment in
collecting comparable data on
different disabilities.6,7 The global
prevalence estimates that are most
frequently cited by multilateral
agencies, such as the World Health
Organization (WHO),3,7 the United
Nations Children’s Fund,2 the United
Nations Educational, Scientific
and Cultural Organization,6 the
Office of the United Nations High
Commissioner for Refugees,8 the
World Bank Group,5 and, more
recently, the US Agency for
International Development,9 were
first published in 2008 on the basis of
the WHO’s Global Burden of Disease
Study (GBD) 2004.10 The GBD
estimated that in 2004, at least 93
million children and adolescents
(0–15 years) worldwide (5.1% of the
global total) lived with a moderate-to-
severe disability, and 13 million
(0.7%) had a severe disability.10
These estimates were generated from
4 specific impairments that were
modeled as sequelae of specific health
disorders: epilepsy, intellectual
disability, hearing loss, and vision
loss. However, the reported estimates
excluded children and adolescents
with mild impairments and were
based on limited data sources.
Additionally, the proportion of
preschool-aged children with
disabilities, who may be the most
likely to benefit from early childhood
intervention services, was not
reported.
Updated and improved estimates of
children and adolescents with
disabilities are needed to better
quantify the disease burden and the
resources required to address the
needs and rights of these children as
mandated by the SDGs,1,11 the
Convention on the Rights of the
Child,12 the Convention on the Rights
of Persons with Disabilities,13 and the
subsisting resolution of the World
Health Assembly on Disability14
and in line with the International
Classification of Functioning,
Disability, and Health (ICF).15 Such
data are also needed to monitor
progress under the SDG era. We,
therefore, set out to report the
prevalence of childhood epilepsy,
intellectual disability, vision loss, or
hearing loss among children and
adolescents (,20 years) and the
associated years lived with disability
(YLD) on the basis of data from the
GBD 201716,17 to complement and
update our earlier report for children
,5 years of age from the GBD 2016.18
METHODS
The GBD provides estimates of non-
fatal outcomes for “impairments”
(used interchangeably with
“disabilities” in the current article), as
part of the annual comprehensive
assessment of incidence, prevalence,
and YLD for several health conditions
across 195 countries and territories.
Impairments are defined as sequelae
of multiple causes for which better
data are available to estimate the
overall occurrence than for each
underlying cause. Four such
impairments are developmental
intellectual disability, epilepsy,
hearing loss, and vision loss. Case
definitions and diagnostic criteria for
these impairments were based on
International Classification of
Diseases, Ninth Revision (ICD-9) and
International Classification of
Diseases, 10th Revision (ICD-10)
codes, complemented with relevant
guidelines such as the Diagnostic and
Statistical Manual of Mental Disorders,
Fourth Edition19 and the Guidelines
for Epidemiologic Studies on
Epilepsy.20 A detailed description of
the GBD conceptual framework for
epilepsy is reported elsewhere.21
Disorders of intellectual development
in the ICD-9 and ICD-10 codes are
termed as “developmental intellectual
disability” or simply “intellectual
disability” in this article and were
grouped into 5 bands on the basis of
IQ scores: borderline, mild, moderate,
severe, and profound intellectual
disability. Hearing and visual
impairments were similarly classified
into bands of severity corresponding
to frequency response and visual
acuity cutoffs, respectively. These 4
disabilities were selected for
comparability with the GBD 2004
estimates for childhood disabilities.
The detailed methodologic techniques
used for estimating the burden of
each impairment have been reported
previously16–18 and are presented in
the Supplemental Information. In
brief, the estimation for each
condition started with the
compilation of all available data
inputs from systematic reviews of
the literature, hospital and claims
databases, health surveys, case
notification systems, cohort studies,
and multinational survey data. All
input data for GBD 2017 are available
at the Global Health Data Exchange
(http://ghdx.healthdata.org/gbd-
2017/data-input-sources). A total of
1675 sources were analyzed for data
on the prevalence of intellectual
disability (57), hearing loss (355),
2 OLUSANYA et al
TABLE 1 Global and Regional Age-Specific Prevalence of and YLD for Epilepsy in 2017
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
High-income North America
Prevalence 131 803 (107 432–159 399) 199 970 (157 616–246 093) 216 420 (168 746–265 722) 216 711 (171 356–265 789) 789 737 (632 514–948 176)
Cases per 100 000 767 (625–927) 890 (701–1095) 920 (717–1129) 920 (727–1128) 867 (695–1041)
YLD 51 974 (37 050–69 051) 75 662 (53 611–104 677) 79 999 (55 802–109 880) 77 882 (54 747–107 040) 295 570 (211 251–403 410)
Rate per 100 000 302 (216–402) 337 (238–466) 340 (237–467) 331 (232–454) 325 (232–443)
Western Europe
Prevalence 126 468 (100 007–156 598) 188 957 (144 255–237 135) 196 335 (151 269–242 173 202 926 (157 762–249 314) 739 764 (574 153–903 671)
Cases per 100 000 712 (563–882) 803 (613–1008) 845 (651–1042) 865 (673–1063) 802 (622–979)
YLD 48 964 (34 429–67 257) 70 905 (49 050–98 578) 72 145 (49 296–98 731) 72 754 (50 216–100 092) 274 710 (192 230–373 788)
Rate per 100 000 276 (194–379) 301 (209–419) 310 (212–425) 310 (214–427) 298 (208–405)
Central Europe, Eastern
Europe, and Central Asia
Prevalence 189 861 (156 308–226 756) 275 179 (221 331–336 004) 256 698 (207 995–311 453) 247 331 (203 706–297 748) 1 004 098
(839 357–1 194 942)
Cases per 100 000 837 (689–1000) 1001 (805–1222) 1066 (864–1293) 1083 (892–1304) 980 (820–1167)
YLD 83 351 (60 394–108 332) 117 909 (86 351–153 388) 108 160 (78 760–144 448) 102 209 (75 128–136 169) 427 137 (315 890–554 788)
Rate per 100 000 368 (266–478) 429 (314–558) 449 (327–600) 448 (329–596) 417 (308–542)
Latin America and the
Caribbean
Prevalence 449 630 (370 510–548 055) 575 028 (459 495–713 720) 609 379 (483 554–749 149) 672 801 (550 138–818 731) 2 420 438
(1 972 412–2 917 913)
Cases per 100 000 1106 (911–1348) 1163 (929–1443) 1237 (981–1521) 1347 (1101–1639) 1213 (988–1462)
YLD 196 721 (145 687–256 747) 245 611 (178 296–324 113) 253 267 (184 956–339 349) 267 238 (198 161–357 961) 1 013 135
(747 175–1 338 725)
Rate per 100 000 484 (358–631) 497 (361–655) 514 (375–689) 535 (397–717) 508 (374–671)
Southeast Asia, East Asia, and
Oceania
Prevalence 737 521 (605 450–893 982) 945 540
(750 994–1 164 348)
958 185
(773 663–1 184 098)
962 589
(783 522–1 177 510)
3 793 040
(3 141 571–4 560 916)
Cases per 100 000 664 (545–804) 701 (557–863) 703 (567–868) 692 (563–846) 687 (569–826)
YLD 331 971 (248 485–440 416) 420 846 (308 919–561 459) 423 461 (308 930–564 083) 419 264 (308 153–556 904) 1 681 681
(1 267 440–2 163 937)
Rate per 100 000 299 (224–396) 312 (229–416) 310 (227–414) 301 (221–400) 305 (230–392)
South Asia
Prevalence 1 134 129
(892 519–1 402 382)
1 592 310
(1 216 048–2 021 679)
1 626 659
(1 248 656–2 046 161)
1 626 693
(1 279 219–2 022 196)
6 207 938
(5 071 432–7 483 407)
Cases per 100 000 804 (633–994) 889 (679–1129) 915 (702–1151) 914 (719–1136) 875 (715–1055)
YLD 547 600 (384 538–732 918) 760 878
(545 412–1 049 013)
772 626
(562 422–1 054 172)
760 804
(549 690–1 019 818)
2 952 475
(2 180 425–3 869 281)
Rate per 100 000 388 (273–519) 425 (304–586) 434 (316–593) 428 (309–573) 416 (307–545)
Sub‐Saharan Africa
Prevalence 1 324 612
(1 044 953–1 668 665)
1 445 699
(1 089 817–1 874 924)
1 327 538
(1 012 314–1 723 209)
1 174 404
(905 551–1 483 284)
5 610 340
(4 407 396–7 044 475)
Cases per 100 000 1027 (810–1294) 980 (739–1271) 1017 (776–1321) 1062 (819–1341) 1016 (799–1276)
YLD 631 083 (455 159–836 628) 654 829 (453 942–909 475) 594 123 (408 058–828 262) 513 862 (358 361–705 617) 2 561 263
(1 817 398–3 446 823)
Rate per 100 000 489 (353–649) 444 (308–617) 455 (313–635) 465 (324–638) 464 (329–624)
North Africa and the Middle
East
Prevalence 529 020 (425 793–647 712) 605 404 (476 471–745 640) 513 903 (406 382–628 706) 439 954 (351 097–534 851) 2 216 563
(1 779 281–2 654 106)
Cases per 100 000 1025 (825–1255) 980 (771–1207) 908 (718–1111) 838 (669–1019) 942 (756–1128)
YLD 236 221 (173 908–315 055) 264 780 (193 166–360 277) 224 422 (163 680–298 144) 190 429 (137 334–255 005) 975 171 (719 368–1 300 365)
Rate per 100 000 458 (337–611) 429 (313–583) 397 (289–527) 363 (262–486) 415 (306–553)
Global
Prevalence 4 704 742
(3 906 017–5 688 824)
5 951 176
(4 780 635–7 281 786)
5 825 559
(4 699 604–7 042 917)
5 674 377
(4 682 960–6 831 607)
23 251 109
(19 477 175–27 607 857
Cases per 100 000 867 (720–1048) 900 (723–1101) 916 (739–1107) 920 (760–1108) 896 (751–1064)
YLD 2 161 753
(1 622 637–2 784 049)
2 661 547
(1 961 247–3 478 308)
2 576 792
(1 943 858–3 419 294)
2 456 333
(1 856 830–3 223 372)
10 371 105
(7 852 990–13 253 967)
Rate per 100 000 398 (299–513) 403 (297–526) 405 (306–537) 398 (301–523) 400 (303–511)
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TABLE 2 Global and Regional Age-Specific Prevalence of and YLD for Intellectual Disability in 2017
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
High-income North
America
Prevalence 312 301 (242 878–382 044) 406 645 (316 939–500 868) 421 064 (328 142–518 193) 414 992 (323 170–511 232) 1 631 108
(1 272 711–2 004 735)
Cases per
100 000
1817 (1413–2223) 1809 (1410–2228) 1789 (1394–2202) 1761 (1372–2170) 1792 (1398–2202)
YLD 56 625 (42 735–71 313) 75 118 (55 834–96 354) 77 205 (57 942–99 252) 74 525 (55 493–94 510) 296 285 (222 764–374 979)
Rate per
100 000
329 (249–415) 334 (248–429) 328 (246–422) 316 (236–401) 325 (245–412)
Western Europe
Prevalence 306 760 (244 393–366 154) 407 635 (323 805–486 663) 398 547 (316 114–476 539) 394 895 (315 514–472 494) 1 581 607
(1 257 082–1 888 734)
Cases per
100 000
1727 (1376–2062) 1733 (1377–2069) 1715 (1360–2051) 1684 (1345–2015) 1714 (1362–2047)
YLD 58 830 (44 214–76 755) 79 235 (59 655–103 358) 77 719 (58 698–102 767) 76 870 (57 392–100 563) 306 181 (231 706–397 589)
Rate per
100 000
331 (249–432) 337 (254–439) 334 (253–442) 328 (245–429) 332 (251–431)
Central Europe,
Eastern Europe,
and Central Asia
Prevalence 464 555 (372 176–551 946) 566 007 (456 083–671 043) 490 842 (396 378–579 410) 456 221 (369 000–539 606) 2 085 228
(1 684 719–2 467 164)
Cases per
100 000
2048 (1641–2434) 2058 (1658–2440) 2038 (1646–2406) 1998 (1616–2363) 2036 (1645–2409)
YLD 96 975 (74 084–123 808) 123 931 (93 748–158 428) 108 941 (82 212–141 470) 100 356 (75 919–129 790) 450 975 (344 233–576 327)
Rate per
100 000
428 (327–546) 451 (341–576) 452 (341–587) 440 (333–568) 440 (336–563)
Latin America and
the Caribbean
Prevalence 672 585 (546 288–790 809) 793 565 (640 531–936 587) 771 280 (620 371–911 461) 757 768 (609 956–895 890) 3 170 947
(2 566 782–3 741 437)
Cases per
100 000
1654 (1343–1944) 1605 (1295–1894) 1565 (1259–1850) 1517 (1221–1794) 1589 (1286–1875)
YLD 163 130 (122 299–205 398) 192 502 (141 828–249 593) 186 842 (138 637–245 523) 180 520 (133 886–238 899) 765 956 (572 889–985 737)
Rate per
100 000
401 (301–505) 389 (287–505) 379 (281–498) 361 (268–478) 384 (287–494)
Southeast Asia, East
Asia, and Oceania
Prevalence 1 989 600
(1 551 695–2 417 553)
2 388 846
(1 858 076–2 909 389)
2 366 591
(1 837 990–2 863 620)
2 342 392
(1 825 186–2 833 713)
9 635 177
(7 508 265–11 680 166)
Cases per
100 000
1790 (1396–2175) 1770 (1377–2156) 1735 (1348–2100) 1683 (1311–2036) 1745 (1360–2116)
YLD 338 527 (261 223–424 819) 409 425 (314 267–510 283) 406 080 (315 679–509 454) 400 529 (312 259–498 027) 1 647 992
(1 282 960–2 052 003)
Rate per
100 000
305 (235–382) 303 (233–378) 298 (231–374) 288 (224–358) 299 (232–372)
South Asia
Prevalence 8 814 255
(6 626 639–10 976 227)
10 915 694
(8 235 801–13 631 549)
10 497 333
(7 918 391–13 093 706)
10 172 283
(7 644 114–12 708 838)
42 491 040
(31 992 788–53 011 211)
Cases per
100 000
6247 (4696–7779) 6093 (4597–7610) 5903 (4453–7363) 5717 (4296–7142) 5990 (4510–7474)
YLD 810 729
(612 510–1 052 819)
1 038 830
(788 263–1 334 037)
1 020 827
(777 147–1 297 493)
987 227
(753 048–1 252 961)
4 042 934
(3 097 570–5 160 238)
Rate per
100 000
575 (434–746) 580 (440–745) 574 (437–730) 555 (423–704) 570 (437–727)
Sub‐Saharan Africa
Prevalence 3 165 296
(2 481 170–3 837 016)
3 334 212
(2 597 892–4 095 851)
2 843 521
(2 215 008–3 491 657)
2 321 894
(1 805 326–2 855 238)
12 578 273
(9 852 736–15 399 332)
Cases per
100 000
2455 (1924–2976) 2261 (1762–2777) 2179 (1698–2676) 2099 (1632–2581) 2279 (1785–2790)
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epilepsy (455), and vision loss (808).
Efforts were made to (1) optimize the
comparability of data derived from
various sources by using different
methods, (2) find a consistent set of
estimates across prevalence data, and
(3) generate estimates for locations
with sparse or no data by using
available information from other
locations combined with covariates.
Prevalence estimates were produced
by using DisMod-MR 2.1, a statistical
modeling technique developed for the
GBD project (Supplemental Fig 5).22
This is a Bayesian meta-regression
tool that synthesizes epidemiological
data for fatal and non-fatal health
outcomes from disparate settings and
sources, adjusting for different case
definitions, diagnostic criteria, or
sampling methods, to generate
internally consistent estimates by
geographical location, year, age group,
and sex. The validity of DisMod has
been widely reported.16–18,22
YLD, defined as the years of life lived
with a condition in a less than ideal
health state, are designed to provide
a comparable measure of disease
burden across diverse health
conditions and impairments rather
than a measure of functional status,
as described in ICF.15 To calculate
YLD for the 4 disabilities, the
estimated prevalence of each
disability was multiplied by an
assigned disability weight. Disability
weights are the population
assessment of magnitude of health
loss from specific health outcomes
measured on a scale from 0 to 1, in
which 0 equals a state of perfect
health and 1 equals death. The
disability weights were estimated
from multicountry population-based
surveys, as described in detail
elsewhere.18,23
The global estimates of the
prevalence and YLD for the 4
disabilities in children and
adolescents were disaggregated by
age group (children: ,1, 1–4, 5–9
years; adolescents: 10–14 and 15–19
years), sex, and geographical regions
(high-income North America, Western
Europe, Central and Eastern Europe
and Central Asia, Latin America and
the Caribbean, Southeast and East
Asia and Oceania, South Asia, Sub-
Saharan Africa, and North Africa and
the Middle East). The selected
locations are not geopolitical units,
but groupings of countries created by
GBD for analytical purposes. All
computations in the GBD were
conducted 1000 times to propagate
uncertainty around the estimates for
prevalence and YLD. At every step in
the modeling process, the
distributions were assessed for the
sampling error of data inputs, the
uncertainty of data corrections for
measurement errors, the uncertainty
in coefficients from model fit, and the
uncertainty of severity distributions
and disability weights. The
corresponding uncertainty intervals
(UIs) for prevalence and YLD
estimates of the 4 disabilities were
defined at the 2.5th and 97.5th value
of 1000 draws. As with all GBD
articles, the substantive data that
formed the basis of this analysis16,17
adhered to the Guidelines for
Accurate and Transparent Health
Estimates Reporting, which include
recommendations on the
documentation of data sources,
TABLE 2 Continued
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
YLD 537 270 (403 404–681 216) 502 903 (371 463–654 997) 427 855 (318 385–563 513) 344 876 (257 747–450 141) 1 978 503
(1 492 394–2 545 605)
Rate per
100 000
417 (313–528) 341 (252–444) 328 (244–432) 312 (233–407) 358 (270–461)
North Africa and
the Middle East
Prevalence 2 095 975
(1 607 222–2 594 440)
2 407 074
(1 843 226–2 986 253)
2 134 977
(1 635 729–2 648 684)
1 888 277
(1 448 419–2 345 875)
9 063 331
(6 947 456–11 240 448)
Cases per
100 000
4062 (3115–5028) 3896 (2984–4834) 3773 (2891–4681) 3596 (2759–4468) 3853 (2954–4779)
YLD 247 026 (186 292–312 698) 277 132 (211 358–354 743) 244 547 (186 614–310 299) 214 982 (164 447–274 406) 1 049 302
(801 194–1 335 594)
Rate per
100 000
479 (361–606) 449 (342–574) 432 (330–548) 409 (313–523) 446 (341–568)
Global
Prevalence 18 008 445
(13 909 115–22 144 997)
21 463 907
(16 582 655–26 376 300)
20 163 862
(15 573 910–24 783 030)
19 007 495
(14 683 193–23 427 643)
83 209 866
(64 448 368–102 067 901)
Cases per
100 000
3318 (2563–4080) 3246 (2508–3989) 3169 (2448–3895) 3083 (2382–3800) 3207 (2484–3934)
YLD 2 349 727
(1 817 711–2 945 999)
2 754 614
(2 118 761–3 466 366)
2 603 898
(2 016 091–3 243 552)
2 437 342
(1 889 411–3 031 441)
10 753 999
(8 286 290–13 378 933)
Rate per
100 000
433 (335–543) 417 (320–524) 409 (317–510) 395 (306–492) 414 (319–516)
PEDIATRICS Volume 146, number 1, July 2020 5
TABLE 3 Global and Regional Age-Specific Prevalence of and YLD for Hearing Loss in 2017
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
High-income North
America
Prevalence 258 142 (225 327–295 461) 478 573 (426 090–537 100) 526 205 (471 867–585 743) 733 490 (664 602–818 883) 2 017 260
(1 870 427–2 183 386)
Cases per
100 000
1502 (1311–1719) 2129 (1895–2389) 2236 (2005–2489) 3113 (2821–3475) 2216 (2054–2398)
YLD 12 408 (8680–17 110) 22 325 (15 402–30 559) 26 443 (18 237–36 819) 30 600 (21 450–41 400) 93 525 (65 864–126 933)
Rate per
100 000
72 (50–100) 99 (69–136) 112 (77–156) 130 (91–176) 103 (72–139)
Western Europe
Prevalence 226 464 (198 409–259 596) 454 724 (401 634–515 000) 510 865 (453 338–573 776) 854 951 (768 534–958 165) 2 064 471
(1 900 504–2 243 406)
Cases per
100 000
1275 (1117–1462) 1933 (1708–2190) 2198 (1951–2469) 3646 (3277–4086) 2237 (2059–2431)
YLD 9166 (6304–12 735) 16 542 (11 121–23 162) 18 457 (12 695–25 847) 24 027 (16 478–34 327) 69 441 (48 083–96 832)
Rate per
100 000
52 (35–72) 70 (47–98) 79 (55–111) 102 (70–146) 75 (52–105)
Central Europe,
Eastern Europe,
and Central Asia
Prevalence 446 534 (393 229–505 136) 867 575 (761 631–978 052) 853 600 (759 658–961 526) 1 156 592
(1 039 959–1 289 852)
3 355 115
(3 098 211–3 626 580)
Cases per
100 000
1969 (1734–2227) 3155 (2769–3556) 3545 (3155–3993) 5066 (4555–5649) 3276 (3025–3541)
YLD 19 754 (13 847–27 355) 34 888 (23 943–48 270) 34 657 (23 805–47 919) 38 964 (27 198–53 796) 130 484 (91 327–179 383)
Rate per
100 000
87 (61–121) 127 (87–176) 144 (99–199) 171 (119–236) 127 (89–175)
Latin America and
the Caribbean
Prevalence 843 578 (744 767–954 872) 1 640 439
(1 443 332–1 839 080)
1 853 695
(1 648 833–2 080 510)
2 670 666
(2 406 587–2 973 854)
7 076 049
(6 546 644–7 652 670)
Cases per
100 000
2074 (1831–2348) 3317 (2919–3719) 3762 (3347–4223) 5347 (4818–5954) 3546 (3280–3835)
YLD 36 917 (25 862–51 437) 64 279 (43 830–88 858) 72 599 (50 013–101 588) 87 004 (60 705–120 938) 265 671 (184 402–365 704)
Rate per
100 000
91 (64–126) 130 (89–180) 147 (102–206) 174 (122–242) 133 (92–183)
Southeast Asia, East
Asia, and
Oceania
Prevalence 2 937 855
(2 637 971–3 247 557
5 847 100
(5 185 984–6 566 636)
6 652 840
(5 969 283–7 447 327)
9 517 169
(8 599 529–10 544 702)
25 253 888
(23 356 813–27 245 250)
Cases per
100 000
2643 (2374–2922) 4333 (3844–4867) 4878 (4377–5460) 6837 (6178–7575) 4574 (4231–4935)
YLD 147 715 (103 706–203 433) 258 411 (179 943–352 506) 295 134 (205 286–407 958) 346 117 (242 624–475 054) 1 070 358
(750 476–1 466 477)
Rate per
100 000
133 (93–183) 192 (133–261) 216 (151–299) 249 (174–341) 194 (136–266)
South Asia
Prevalence 3 931 287
(3 566 450–4 315 347)
7 908 429
(7 057 869–8 818 810)
8 847 058
(7 976 611–9 814 130)
12 033 855
(10 927 238–13 319 010)
33 081 529
(30 758 299–35 615 041)
Cases per
100 000
2786 (2528–3058) 4415 (3940–4923) 4975 (4485–5519) 6763 (6141–7485) 4664 (4336–5021)
YLD 209 056 (146 539–286 880) 359 966 (252 910–485 911) 399 390 (275 291–552 742) 457 025 (321 410–630 307) 1 455 912
(1 023 230–1 979 015)
Rate per
100 000
148 (104–203) 201 (141–271) 225 (155–311) 257 (181–354) 205 (144–279)
Sub-Saharan Africa
Prevalence 3 694 805
(3 352 273–4 064 331)
6 576 843
(5 912 292–7 295 890)
6 363 670
(5 763 444–7 037 152)
7 182 174
(6 591 941–7 868 098)
24 215 356
(22 583 511–25 985 485)
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estimation methods, statistical
analysis, and statistical code.24
RESULTS
Globally, the population of children
and adolescents was ∼2.6 billion in
2017, of whom 291.2 million (95%
UI: 249.9–335.4), or 11.2% (95% UI:
10.0–12.5), were estimated to have 1
of the 4 disabilities examined (Tables
1–4). Approximately 152.3 million
(52.3%) were male, although the sex
pattern varied across the disabilities.
The prevalence of these disabilities
increased with age, from 6.1% among
all the ∼138 million children aged
,1 year to 13.9% among the roughly
616 million adolescents aged 15 to
19 years. A total of 16 million (95%
UI: 13.4–18.9 [5.5%]) lived in high-
income countries, and 275.2 million
(95% UI: 236.4–316.5 [94.5%]) lived
in LMIC. Of all the children and
adolescents with disabilities, 8.4
million (2.9%) were aged ,1 year,
47.9 million (16.4%) were aged 1 to
4 years, 73.5 million (25.2%) were
aged 5 to 9 years, 75.9 million
(26.1%) were aged 10 to 14 years,
and 85.6 million (29.4%) were aged
15 to 19 years. Thus, a total of 205.6
million (70.6%) were ,15 years of
age. These 4 disabilities accounted for
28.9 million YLD (or 19.9%) of the
overall 145.3 million (95% UI:
106.9–189.7) YLD among children
and adolescents from all causes of
fatal and non-fatal outcomes included
in the GBD 2017.
The prevalence of hearing loss rose
from 0.9% among children aged
,1 year to 5.9% (95% UI:
5.4%–6.5%) among adolescents aged
15 to 19 years (Fig 1). Vision loss
rose from 1.1% among children aged
,1 year to 3.9% (95% UI:
3.4%–4.6%) among adolescents aged
15 to 19 years. The prevalence of
intellectual disability and epilepsy
remained largely constant at ∼3%
and 0.9%, respectively, in all age
groups. Among all children and
adolescents, the disability-specific
prevalence was 0.9% (95% UI:
0.8%–1.1%) for epilepsy, 3.2% (95%
UI: 2.5%–3.9%) for intellectual
disability, 3.1% (95% UI: 2.7%–3.6%)
for vision loss, and 4.0% (95% UI:
3.7%–4.3%) for hearing loss.
However, epilepsy and intellectual
disability were associated with the
highest YLD in all age groups, which
were significantly higher than
sensory disabilities.
South Asia accounted for the highest
prevalence of intellectual disability
(6.0% [95% UI: 4.5%–7.5%]), hearing
loss (4.7% [95% UI: 4.3%–5.0%]),
and vision loss (3.7% [95% UI:
3.2%–4.2%]), whereas Latin America
and the Caribbean recorded the
highest prevalence of epilepsy (1.2%
[95% UI: 1.0%–1.5%]), as shown in
Fig 2. Epilepsy was least prevalent in
Southeast and East Asia and Oceania
(0.7% [95% UI: 0.6%–0.8%]), and
intellectual disability was least
prevalent in Latin America and the
Caribbean (1.6% [95% UI:
1.3%–1.9%]), whereas vision loss
TABLE 3 Continued
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
Cases per
100 000
2866 (2600–3152) 4460 (4009–4947) 4877 (4417–5393) 6493 (5959–7113) 4387 (4092–4708)
YLD 239 641 (167 087–325 126) 355 441 (249 963–475 154) 348 323 (244 318–470 735) 331 536 (234 376–448 129) 1 320 256
(937 865–1 765 546)
Rate per
100 000
186 (130–252) 241 (170–322) 267 (187–361) 300 (212–405) 239 (170–320)
North Africa and
the Middle East
Prevalence 751 019 (652 720–873 241) 1 405 634
(1 230 855–1 586 991)
1 443 894
(1 271 286–1 632 521)
1 941 910
(1 732 125–2 175 269)
5 591 434
(5 144 265–6 077 669)
Cases per
100 000
455 (1265–1692) 2275 (1992–2569) 2552 (2247–2885) 3699 (3299–4143) 2377 (2187–2584)
YLD 30 533 (20 961–42 481) 54 000 (36 989–74 896) 56 630 (38 685–79 072) 63 515 (43 877–88 736) 207 788 (144 685–286 606)
Rate per
100 000
59 (41–82) 87 (60–121) 100 (68–140) 121 (84–169) 88 (62–122)
Global
Prevalence 13 244 864
(11 950 478–14 667 046)
25 468 776
(22 734 486–28 377 208)
27 358 599
(24 627 508–30 360 794)
36 577 235
(33 265 797–40 257 224)
103 904 538
(96 545 635–111 630 666)
Cases per
100 000
2440 (2202–2703) 3852 (3438–4292) 4300 (3871–4772) 5933 (5396–6530) 4005 (3721–4302)
YLD 711 795 (499 549–978 438) 1 177 588
(826 177–1 586 023)
1 264 660
(880 741–1 742 484)
1 395 869
(982 697–1 908 896)
4 662 724
(3 290 463–6 304 785)
Rate per
100 000
131 (92–180) 178 (125–240) 199 (138–274) 226 (159–310) 180 (127–243)
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TABLE 4 Global and Regional Age-Specific Prevalence of and YLD for Vision Loss in 2017
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
High-income North
America
Prevalence 152 623
(118 137–187 434)
290 067 (216 569–380 633) 325 847 (245 317–433 303) 332 019 (260 911–415 580) 1 114 609
(893 445–1 366 118)
Cases per
100 000
888 (687–1090) 1290 (963–1693) 1385 (1042–1841) 1409 (1107–1764) 1224 (981–1501)
YLD 6825 (4491–9800) 12 497 (7946–18 913) 13 922 (9109–20 643) 14 080 (9443–20 526) 48 069 (31 567–70 783)
Rate per
100 000
40 (26–57) 56 (35–84) 59 (39–88) 60 (40–87) 53 (35–78)
Western Europe
Prevalence 276 367
(198 687–374 997)
517 470 (353 529–726 275) 525 529 (358 367–760 147) 518 419 (371 643–710 943) 1 863 897
(1 406 494–2 458 616)
Cases per
100 000
1556 (1119–2111) 2200 (1503–3088) 2261 (1542–3271) 2211 (1585–3031) 2020 (1524–2664)
YLD 12 670 (8363–18 679) 22 999 (14 561–35 761) 23 903 (15 661–36 263) 24 246 (16 137–35 060) 85 277 (56 719–126 152)
Rate per
100 000
71 (47–105) 98 (62–152) 103 (67–156) 103 (69–149) 92 (61–137)
Central Europe,
Eastern Europe,
and Central Asia
Prevalence 564 728
(440 263–703 012)
941 642
(717 458–1 223 861)
868 204
(677 153–1 113 574)
846 765
(688 153–1 039 601)
3 283 489
(2 696 872–3 979 988)
Cases per
100 000
2490 (1941–3100) 3424 (2609–4450) 3605 (2812–4624) 3709 (3014–4553) 3206 (2633–3886)
YLD 23 331 (15 339–33 908) 37 060 (23 671–57 112) 33 650 (22 175–50 785) 32 090 (21 729–46 690) 129 096 (86 179–190 154)
Rate per
100 000
103 (68–150) 135 (86–208) 140 (92–211) 141 (95–204) 126 (84–186)
Latin America and
the Caribbean
Prevalence 740 115
(608 175–891 456)
1 382 342
(1 139 624–1 686 144)
1 722 148
(1 458 855–2 078 414)
2 134 390
(1 864 828–2 454 466)
6 060 394
(5 274 074–6 953 437)
Cases per
100 000
1820 (1495–2192) 2795 (2305–3410) 3495 (2961–4218) 4273 (3733–4914) 3037 (2643–3484)
YLD 35 105 (24 358–49 102) 56 438 (38 220–82 876) 63 224 (43 422–93 124) 71 838 (49 073–102 168) 231 800 (161 066–330 075)
Rate per
100 000
86 (60–121) 114 (77–168) 128 (88–189) 144 (98–205) 116 (81–165)
Southeast Asia, East
Asia, and Oceania
Prevalence 2 249 931
(1 808 000–2 713 770)
3 932 438
(3 111 842–4 917 097)
4 413 990
(3 605 469–5 471 494)
4 703 742
(4 018 023–5 517 485)
15 585 040
(13 235 355–18 269 625)
Cases per
100 000
2024 (1627–2442) 2914 (2306–3644) 3236 (2644–4012) 3379 (2887–3964) 2823 (2397–3309)
YLD 109 196 (76 200–153 579) 166 445 (111 487–245 186) 176 644 (121 421–254 986) 181 132 (126 902–254 871) 653 115 (455 897–924 467)
Rate per
100 000
98 (69–138) 123 (83–182) 130 (89–187) 130 (91–183) 118 (83–167)
South Asia
Prevalence 3 774 616
(3 077 028–4 508 330)
6 439 687
(5 251 987–7 862 311)
7 183 140
(6 119 227–8 571 685)
8 143 890
(7 174 906–9 255 169)
26 038 313
(22 730 901–29 883 169)
Cases per
100 000
2675 (2181–3195) 3595 (2932–4389) 4039 (3441–4820) 4577 (4032–5201) 3671 (3205–4213)
YLD 165 553
(113 090–235 319)
245 087 (163 525–364 047) 249 088 (168 740–368 544) 261 408 (181 428–376 079) 948 988
(648 070–1 367 226)
Rate per
100 000
117 (80–167) 137 (91–203) 140 (95–207) 147 (102–211) 134 (91–193)
Sub‐Saharan Africa
Prevalence 2 648 821
(2 192 343–3 177 168)
4 543 637
(3 814 398–5 446 542)
4 907 105
(4 263 876–5 738 216)
4 973 223
(4 439 848–5 562 714)
17 405 890
(15 387 972–19 716 012)
Cases per
100 000
2055 (1700–2464) 3081 (2587–3693) 3761 (3268–4398) 4496 (4014–5029) 3154 (2788–3572)
YLD 129 586 (91 767–177 285) 178 202 (122 692–257 198) 172 247 (119 122–245 839) 161 966 (113 190–226 755) 667 326 (471 998–937 436)
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(1.2% [95% UI: 1.0%–1.5%]) and
hearing loss (2.2% [95% UI:
2.1%–2.4%] were least prevalent in
high-income North America. South
Asia (0.6% [95% UI: 0.4%–0.7%])
and Latin America and the Caribbean
(0.5% [95% UI: 0.4%–0.7%]) were
associated with the highest YLD rates
for intellectual disability and epilepsy,
respectively. South Asia (107.8
million or 37.5%) and sub-Saharan
Africa (59.8 million or 20.5%)
accounted for more than half of all
children and adolescents with
disabilities (Fig 3). High-income
North America (5.6 million or 1.9%)
and Western Europe (6.2 million or
2.1%) accounted for the lowest
population of children and
adolescents with disabilities.
Globally, mild intellectual disability
(IQ scores of 50–69) was the most
prevalent disability, and mild vision
loss was the least prevalent disability
among the 4 types of disability
(Fig 3). Within regions, mild hearing
loss was the most common disability
in all regions except Central and
Eastern Europe and Central Asia and
Southeast and East Asia and Oceania.
Mild vision loss was the least
prevalent disability in all regions.
Severe epilepsy and severe
intellectual disability were the 2 most
common disabilities with the highest
YLD globally and in all regions. The
burden of epilepsy was more
concentrated in Mexico, Colombia,
and Venezuela in Latin America and
was more concentrated in Gabon, the
Republic of the Congo, and Angola in
sub-Saharan Africa (Fig 4).
Intellectual disability had the highest
prevalence in India (South Asia),
Afghanistan, and Yemen (Middle
East). Hearing loss was most
prevalent in Madagascar (sub-
Saharan Africa) and Myanmar
(Southeast Asia), whereas vision loss
was more widespread and had the
highest prevalence in South Sudan,
the Central African Republic (sub-
Saharan Africa), and Papua New
Guinea (Oceania).
The top 10 countries accounted for
52.8% of all children and adolescents
with epilepsy, 68.0% of children and
adolescents with intellectual
disability, 62.0% of children and
adolescents with hearing loss, and
59.4% of children and adolescents
with vision loss (Supplemental Fig 6).
The top 10 countries accounted for
62.3% of all children and adolescents
with these disabilities. These
countries also accounted for at least
53.5% of the YLD associated with
these conditions. India and China had
the highest population of children
and adolescents with any disability,
with their associated YLD. The United
States was the only high-income
country among the top 10 countries
for any disability. However, in terms
of the highest prevalence and YLD
rates per population, countries with
the highest prevalence were Gabon
for epilepsy, India for intellectual
disability, Madagascar for hearing
loss, and Israel for vision loss. The
underlying causes or risk factors and
their ICD-9 and ICD-10 codes that
formed the basis of the reported
estimates for all disabilities in the
GBD 2017, as well as their
contributions to the aggregate
estimate for each disability, are
summarized in Supplemental Fig 7.
DISCUSSION
Our primary aim was to update the
global estimate of children and
adolescents with disabilities
previously attributed to the GBD
2004 and still widely reported in the
literature.2–9 Although, in our study,
TABLE 4 Continued
No. (95% UI)
1–4 y 5–9 y 10–14 y 15–19 y ,20 y
Rate per
100 000
101 (71–138) 121 (83–174) 132 (91–188) 146 (102–205) 121 (86–170)
North Africa and the
Middle East
Prevalence 1 270 261
(1 006 150–1 584 554)
2 128 785
(1 665 430–2 721 426)
2 186 398
(1 774 129–2 745 766)
2 218 003
(1 877 690–2 634 071)
7 960 528
(6 721 789–9 429 083)
Cases per
100 000
2462 (1950–3071) 3446 (2696–4405) 3864 (3136–4853) 4224 (3576–5017) 3384 (2858–4009)
YLD 56 999 (38 277–81 141) 82 725 (53 508–125 192) 79 230 (53 191–119 232) 76 351 (52 324–110 075) 304 847 (206 858–442 931)
Rate per
100 000
110 (74–157) 134 (87–203) 140 (94–211) 145 (100–210) 130 (88–188)
Global
Prevalence 11 902 507
(9 685 418–14 340 209)
20 584 553
(16 619 635–25 501 975)
22 554 407
(18 878 363–27 433 881)
24 339 696
(21 124 978–28 083 187)
80 857 974
(69 402 207–94 059 458)
Cases per
100 000
2193 (1785–2642) 3113 (2514–3857) 3545 (2967–4312) 3948 (3427–4556) 3116 (2675–3625)
YLD 549 006
(378 690–770 472)
818 335
(546 869–1 207 657)
829 363
(566 152–1 214 034)
842 676
(582 361–1 198 086)
3 133 280
(2 171 484–4 467 090)
Rate per
100 000
101 (70–142) 124 (83–183) 130 (89–191) 137 (94–194) 121 (84–172)
PEDIATRICS Volume 146, number 1, July 2020 9
we did not capture the full spectrum
of all possible childhood disabilities,
our analysis reveals that the number
of children and adolescents with
disabilities is at least 291 million
globally and that the prevalence
increases with age. Among children
and adolescents ,15 years, the
estimate of children and adolescents
with these 4 disabilities is more than
twice the 2004 estimate of 93 million.
The substantially higher estimate can
be attributed to several factors
besides the modest impact of the
∼6.6% and 4.1% rise in the global
population of children and
adolescents ,15 and ,20 years,
respectively, between 2004 and
2017.25 Firstly, the number and
variety of data sources used in
generating estimates have increased
substantially since 2004. Secondly,
the modeling techniques have
improved significantly on the basis of
expert contributions from an
increasing number of institutional
and individual collaborators from 146
countries.26 Thirdly, consistent with
the classification recommended by
the ICF, the GBD 2017 estimates
include disabilities of varying degrees
of severity from slight or mild to
profound for each disability. Lastly,
there is now an internationally agreed
on framework for evaluating
estimates of health from statistical
modeling, which has been strictly
followed by the GBD since 2015.24
The GBD modeling efforts are meant
to bridge a critical gap in the
epidemiology of developmental
disorders resulting from several
conceptual and operational
challenges in measuring disabilities in
children and adolescents.27,28 As with
most health conditions, the dearth of
population-based data for specific
disabilities, especially in LMIC, has
compelled a growing reliance on the
statistical estimation of health
outcomes as an interim step to guide
health policy and intervention. The
implicit philosophy underpinning
these efforts is that the absence of
conventional epidemiological data is
not evidence of the absence of
a health condition. Thus, GBD is an
essential, independent, and up-to-
date source of alternative data for
policy-makers and decision-makers in
global health, especially for countries
with poor or no data.2,3
However, it is helpful to evaluate the
plausibility of the GBD estimates in
the absence of comparable global
estimates from other reputable
sources. The global estimate of 0.9%
(95% UI: 0.8%–1.1%) for epilepsy
among all children and adolescents
appears plausible on the basis of
evidence in the literature, suggesting
a global prevalence of between 0.5%
and 1%.29,30 In addition, the estimate
of 1.0% (95% UI: 0.8%–1.3%) for
sub-Saharan Africa is consistent with
the 0.9% reported in the most
comprehensive systematic review on
epilepsy to date from this region.31
The GBD estimate for intellectual
disability of 3.2% (95% UI:
FIGURE 1
Global age-specific prevalence of and YLD for childhood epilepsy, intellectual disability, hearing loss
and vision loss in 2017.
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2.5%–3.9%) was higher than the
estimate of 1.8% reported in 1 meta-
analysis of population-based studies,
possibly because of the inclusion of
children and adolescents with
comorbid autism spectrum disorder
and cerebral palsy secondary to
neonatal encephalopathy in the
GBD.32,33 South Asia substantially
contributed to the reported global
estimates for intellectual disability,
and the age-specific GBD estimates
for this region are supported by
a recent robust population-based
study from India in which
a prevalence of 5.2% was reported.34
Sensory disabilities are perhaps the
most researched childhood
disabilities worldwide. Several
studies in school-aged children
support the reported estimates for
vision loss and hearing loss, with
most suggesting that the GBD
estimates were conservative.35–38 For
example, in 1 systematic review of
childhood hearing loss, a prevalence
of between 0.8% and 46.7% was
reported across 26 well-conducted
studies from different regions,36
whereas 2 population-based studies
from Canada and the United Sates
revealed estimates of between 4.5%
and 7.9%, compared with a GBD
estimate of 2.2% for North America.
More crucially, these findings
underscore the need to develop local
capacity toward early identification
and timely on-going support for
children and adolescents with any
disability and their families,
especially in high-burden LMIC. The
unique challenges faced by children
with disabilities as they transition
into adolescence also need to be
recognized and addressed.39
This study has several limitations
worth emphasizing. Most importantly,
our main finding must be regarded as
a conservative estimate of children
with disabilities in general because
this study was restricted to 4
conditions. The inclusion of
conditions such as cerebral palsy
without comorbid intellectual
disability would have increased the
reported estimates in our article.
Additionally, the GBD 2017 has
methodologic limitations that have
been extensively described in
previous publications in accordance
with the Guidelines for Accurate and
Transparent Health Estimates
Reporting.16–18 For example, the 95%
UIs around estimates for regions with
sparse data are still wide. Most of the
uncertainty in the YLD estimates
results from the current limitations in
the determination of disability
weights that may be minimized in the
future by removing some of the
ambiguities in lay descriptions and
increasing the volume of survey data.
In addition, despite the continuous
efforts toward improving the GBD
methodology, concerns remain on
estimating the prevalence of
disabilities solely as sequelae of
health conditions.2,3,40 Furthermore,
the estimates do not fully reflect the
complex and dynamic relationship
between health conditions and
contextual personal or environmental
FIGURE 2
Regional prevalence of and YLD for childhood epilepsy, intellectual disability, hearing loss and vision
loss in 2017.
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factors, as envisaged under the ICF,
and so provide a limited picture of
disability.15 Finally, it was difficult to
completely and precisely account for
children with multiple disabilities and
across multiple developmental
domains. These considerations reveal
the need for complementary
nationally representative disability
data, such as those published
periodically by the United Nations
Children’s Fund and the WHO, that
can be used as additional data inputs
for the GBD. Although estimates of
disabilities from both statistical
modeling and household surveys are
not definitive, they reflect current
knowledge and the best available
evidence to inform policies and
interventions.
CONCLUSIONS
In the most recent GBD, it is shown
that the number of children and
adolescents with disabilities globally
far exceeds the estimate in 2004. The
burden of disability is substantial
from early childhood and
corroborates our earlier report on the
need to address the quality of life of
many beneficiaries of the child
survival programs during the era of
the Millennium Development Goals
(2000–2015).18 The risk likely to be
faced by the affected children and
adolescents of not realizing their full
potential, especially in LMIC, as
envisaged under the SDGs era, is real
and disturbing. Regardless of the
inherent limitations of modeled
estimates, the findings from our
analysis are plausible and insightful.
These findings shed light on the high
and growing health needs among
child survivors that warrant
significant investments and should be
a wake-up call to public health
leaders and advocates globally. A
committed global leadership will
ensure that these and other
vulnerable children and adolescents
are truly not left behind in
accordance with the obligations
under the Convention on the Rights of
the Child and the Convention on the
Rights of Persons with Disabilities.
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FIGURE 3
Regional ranking of childhood epilepsy, intellectual disability, hearing loss, and vision loss by
severity among children and adolescents based on estimates of prevalence and YLD in 2017. Colors
correspond to the ranking of disability by severity, with dark red indicating the most common
disability and dark green indicating the least common disability for the location indicated. The
numbers inside each box indicate the ranking.
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FIGURE 4
Global distribution of childhood epilepsy, intellectual disability, hearing loss and vision loss in 2017. A, Epilepsy, both sexes, ,20 years, 2017, prevalent
cases per 100 000. B, Developmental intellectual disability, both sexes, ,20 years, 2017, prevalent cases per 100 000. C, Hearing loss, both sexes, ,20
years, 2017, prevalent cases per 100 000. D, Blindness and vision impairment, both sexes, ,20 years, 2017, prevalent cases per 100 000.
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FIGURE 4
Continued.
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